Stevenson Search Partners Places Chairperson for Lucy Therapeutics

Stevenson Search Partners is pleased to announce the appointment of Kim Drapkin as Board Chair of Lucy Therapeutics.

Lucy Therapeutics is a biotech company developing proprietary small molecule therapies for complex neurological diseases including Rett syndrome, Parkinson’s and Alzheimer’s. Instead of focusing solely on genetic links, the company analyzes a wide range of drivers central to disease progression, including mitochondrial, environmental and genetic factors.

Ms. Drapkin brings more than 25 years of experience with private and publicly traded biotechnology and pharmaceutical companies. She most recently served as President and CEO of Graphite Bio, which she successfully merged with LENZ Therapeutics.